Detecting Multiple Cancers and Other Diseases From a Single Blood Sample

Why It Matters

MethylScan could transform early disease screening by offering a low‑cost, multi‑disease liquid biopsy, reducing reliance on invasive procedures and enabling broader population monitoring.

Key Takeaways

• MethylScan uses cfDNA methylation, not mutation detection.
• 98% specificity, 63% overall cancer detection.
• Detects 80% early liver cancer with >90% specificity.
• Identifies tissue origin, aiding targeted follow‑up.
• Costs under $20 per test, enabling wide screening.

Pulse Analysis

Liquid biopsies have reshaped oncology diagnostics, yet most commercial tests focus on a narrow set of genetic mutations and demand deep sequencing, driving up costs. MethylScan sidesteps these constraints by targeting DNA methylation patterns, a more abundant and tissue‑specific signal. By enzymatically depleting unmethylated fragments that dominate the bloodstream, the assay slashes required sequencing to 5 Gb, translating to a sub‑$20 price point—an order of magnitude cheaper than many existing panels, making population‑scale screening financially feasible.

The clinical data underscore the test’s promise: across more than a thousand samples, MethylScan delivered 98% specificity while catching 63% of cancers across stages and 55% of early‑stage tumors, a critical metric for improving survival outcomes. Its performance in high‑risk liver cohorts—detecting roughly 80% of malignancies with over 90% specificity—demonstrates utility beyond oncology, extending to chronic disease surveillance. Crucially, the methylation signatures enable precise tissue‑of‑origin identification, guiding clinicians toward targeted imaging and reducing diagnostic ambiguity. The ability to differentiate viral hepatitis from metabolic‑associated liver disease further hints at a broader role in non‑invasive disease stratification.

Looking ahead, MethylScan faces the typical hurdles of validation, regulatory approval, and integration into existing screening pathways. Large‑scale prospective trials will be essential to confirm real‑world sensitivity and to establish reimbursement models. If successful, the technology could catalyze a shift toward universal, blood‑based health monitoring, curbing the need for costly imaging or invasive biopsies and delivering measurable savings to payers. Its cost advantage and multi‑disease scope position it as a compelling contender in the emerging market for comprehensive liquid‑biopsy platforms.